15969-08-1

Basic information

• Product Name: 2-METHOXY-6-NITROPHENOL
• Synonyms: 2-METHOXY-6-NITROPHENOL
• CAS NO: 15969-08-1
• Molecular Formula: C₇H₇NO₄
• Molecular Weight: 169.13478
• Mol File: 15969-08-1.mol
• Article Data: 14

Chemical Properties

• Melting Point: 62 °C (sublm)
• Boiling Point: 260.3±20.0 °C(Predicted)
• Appearance: /
• Density: 1.367±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 7.09±0.24(Predicted)
• CAS DataBase Reference: 2-METHOXY-6-NITROPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHOXY-6-NITROPHENOL(15969-08-1)
• EPA Substance Registry System: 2-METHOXY-6-NITROPHENOL(15969-08-1)

Safety Data

• Hazardous Substances Data: 15969-08-1(Hazardous Substances Data)

Usage

General Description

2-Methoxy-6-nitrophenol is a chemical compound with the molecular formula C7H7NO4. It is a yellow crystalline solid with a slightly phenolic odor. 2-METHOXY-6-NITROPHENOL is mainly used in the manufacturing of dyes, pharmaceuticals, and other organic compounds. It is also used as an intermediate in the synthesis of various organic chemicals. 2-Methoxy-6-nitrophenol is known to be harmful if ingested, inhaled, or in contact with the skin, as it may cause irritation and damage to the respiratory system. Additionally, it is considered hazardous to the environment and should be handled and disposed of with care.

Upstream product

• 64-19-7 acetic acid 
• 90-05-1 2-methoxy-phenol 
• 110-71-4 1,2-dimethoxyethane 
• 60-29-7 diethyl ether 
• 7697-37-2 nitric acid 
• 91004-48-7 4,5-Dimethoxy-3-nitrobenzoic acid 
• 62-53-3 aniline 
• 116496-81-2 acetic acid-(2-methoxy-6-nitro-anilide) 
• 555-03-3 3-nitroanisole 

Downstream Products

• 116668-84-9 3-nitroveratrole 
• 158429-03-9 C₁₂H₁₅NO₄ 
• 663935-09-9 2-isopropoxy-3-methoxynitrobenzene 
• 888731-94-0 (4-benzyloxy-3,5-dichlorophenyl)-[8-(tert-butyldimethylsilyloxy)-2,3-dihydrobenzo[1,4]oxazin-4-yl]-methanone 
• 888731-91-7 2-chloro-N-(2-hydroxy-3-methoxyphenyl)-acetamide 
• 258532-71-7 8-methoxy-4H-benzo[1,4]oxazin-3-one 
• 258532-76-2 8-hydroxy-3-oxo-3,4-dihydro-2H-1,4-benzoxazine 
• 6299-67-8 2,3-dimethoxyaniline 
• 25245-33-4 1-iodo-2,3-dimethoxybenzene 
• 220034-67-3 N-tosyldiscorhabdin C 
• 220034-62-8 {2-[7-Benzyloxy-6-methoxy-1-(toluene-4-sulfonyl)-1H-indol-3-yl]-ethyl}-carbamic acid tert-butyl ester 
• 220034-66-2 C₂₅H₂₁N₃O₄S 
• 220034-64-0 7-(3,5-dibromo-4-hydroxyphenethylamino)-1-tosyl-3,4-dihydropyrrolo[4,3,2-de]quinolin-8(1H)-one 
• 220034-65-1 7-[2-(3-Bromo-4-hydroxy-phenyl)-ethylamino]-1-(toluene-4-sulfonyl)-3,4-dihydro-1H-pyrrolo[4,3,2-de]quinolin-8-one 

Relevant articles and documents

-

-

Water-soluble PDE4 inhibitors for the treatment of dry eye

PDE4 inhibitors have the potential to alleviate the symptoms and underlying inflammation associated with dry eye. Disclosed herein is the development of a novel series of water-soluble PDE4 inhibitors. Our studies led to the discovery of coumarin 18, whic

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.